Dimethyl fumarate

Generic dimethyl fumarate delayed-release capsules are 2nd launch in 3 months Average savings of $4,300/month compared with other generic versions LEHI, Utah, June 24, 2025 /PRNewswire/ -- CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of dimethyl fumarate delayed-release capsules. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. CivicaScript will offer dimethyl fumarate 240 mg capsules for sale to pharmacies for $47 per bottle of 60 capsules – typically a month's supply. CivicaScript recommends that pharmacies charge patients no more than $68 per bottle (CivicaScript's maximum retail price, or MaxRP TM). CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label. CivicaScript will offer the 120 mg and 240 mg strengths of dimethyl fumarate capsules for sale. CivicaScript's MaxRP for dimethyl fumarate is about $4,300 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies. 1 It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price. "Today's launch is yet another step in our journey to make necessary medications more affordable for the patients who need them," said CivicaScript President Brent J. Eberle. "We're bringing transparency and affordability to the generic drug market in a sustainable way – saving money for patients and payers and making medicines more accessible." The launch comes on the heels of a report in The New England Journal of Medicine Catalyst that CivicaScript's abiraterone saved consumers 64% and payers 92% when they switched from other versions of the same drug. CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient. Dimethyl fumarate was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product. While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place. About CivicaScript CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A nonprofit company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency. About dimethyl fumarate For full prescribing information and patient information, including important warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available here. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. MEDIA CONTACT: Liz Power [email protected] +1 860 501 3849 1 Compared with 2021 average reimbursement rate for all strengths of Dimethyl Fumarate. See Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers, Federal Trade Commission Second Interim Staff Report, January 2025, at Fig. A2, Table A (pg. 34), available at SOURCE CivicaScript WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Bengaluru: Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs . The drugmaker has been counting on newer launches such as genetic disorder drug Skyclarys as demand falls for its once top-selling multiple sclerosis medicines in the face of stiff competition in a crowded treatment market. CEO Christopher Viehbacher, who took the helm in 2022, has focused on deals, cost-cutting measures and newer drugs to address investor pressure for growth. The company has been doubling down on its Alzheimer's drug Leqembi , but it has failed to live up to lofty expectations due to concerns over cost, efficacy and side effects. It sells for $26,500 annually in the U.S. The company said it does not expect any material impact from President Trump's sweeping tariffs implemented to date. Biogen said about 75 per cent of its U.S. revenue last year came from products manufactured in the country, which includes Leqembi and spinal muscular atrophy treatment Spinraza. Biogen expects 2025 profit per share of $14.50 to $15.50, compared with its previous forecast of $15.25 to $16.25. It reported an adjusted profit of $3.02 per share for the quarter, compared with analysts' expectations of $2.52 per share, according to estimates compiled by LSEG. U.S. sales of Leqembi, which the company sells with Japan's Eisai, were $52 million for the first quarter ended March 31. The Wall Street consensus estimate was at $54 million, according to brokerage Jefferies. Sales of multiple sclerosis drugs such as Tecfidera fell 11 per cent to $953 million. Sales of rare disease drugs, including Skyclarys and Spinraza, rose 33 per cent to $563 million in the quarter. Revenue rose 6 per cent to $2.43 billion, and came above analysts' average estimate of $2.23 billion. (Reporting by Christy Santhosh and Mariam Sunny in Bengaluru; Editing by Devika Syamnath)